查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1874574

全球血液感染檢測市場

Bloodstream Infection Testing
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 173 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球血液感染檢測市場預計到2030年將達到171億美元

全球血液傳染病檢查市場規模在2024年估計為115億美元，預計到2030年將達到171億美元，在分析期（2024-2030年）內複合年成長率（CAGR）為6.9%。本報告分析的傳統檢測細分市場預計將以7.7%的複合年成長率成長，並在分析期結束時達到127億美元。非傳統檢測細分市場預計在分析期間將以4.9%的複合年成長率成長。

美國市場規模估計為30億美元，而中國市場預計將以10.4%的複合年成長率成長。

據估計，2024年美國血液傳染病檢查市場規模將達30億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到42億美元，在2024年至2030年的分析期間內，複合年成長率（CAGR）將達到10.4%。其他值得關注的區域市場分析包括日本和加拿大，預計在分析期間內，這兩個國家的複合年成長率分別為3.4%和6.3%。在歐洲，德國預計將以約4.2%的複合年成長率成長。

全球血液感染檢測市場－主要趨勢與促進因素概述

為什麼血液傳染傳染病檢查是醫學診斷的基礎

血流感染 (BSI) 檢測在醫學診斷中發揮著至關重要的作用，因為它對於早期發現和治療敗血症至關重要。膿毒症是一種危及生命的疾病，由身體對感染疾病的過度免疫反應所引起。 BSI 由多種病原體引起，包括細菌、真菌和病毒，快速識別這些病原體對於預防其發展為重症膿毒症或敗血性休克至關重要，而這兩種疾病均與高死亡率相關。及時進行 BSI 檢測有助於醫護人員給予適當的抗菌治療，從而降低併發症風險並改善患者預後。作為醫院感染控制的基石，BSI 檢測對於預防感染傳播也至關重要，尤其是在加護病房，因為那裡的患者最為脆弱。

技術創新如何改變血液感染檢測？

血液傳染傳染病檢查領域正因技術的快速發展而發生變革，診斷的速度、準確性和整體性均顯著提升。傳統的血液培養方法需要數天才能出結果，如今正被聚合酵素鏈鎖反應(PCR)、質譜分析和次世代定序(NGS) 等先進的分子診斷技術所補充或取代。這些技術能夠快速鑑定病原體（通常在數小時內），從而實現更早、更有針對性的治療性介入。此外，照護現場檢測 (POC) 設備的出現使血流感染 (BSI) 的診斷更加便捷，有助於在急診和遠端醫療環境中更快地做出決策。人工智慧 (AI) 和機器學習演算法在診斷平台中的應用也提高了對複雜數據的解讀能力，從而帶來更準確的診斷和更完善的患者管理。

影響血液傳染傳染病檢查市場的挑戰和監管壓力有哪些？

血液傳染傳染病檢查市場受到許多挑戰和監管壓力的複雜影響。其中一個關鍵挑戰是需要高靈敏度和高特異性的檢測方法，以準確識別包括難以培養或檢測的病原體在內的多種病原體。這種需求推動了對診斷技術研發和創新的大量投資。同時，美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等監管機構對新檢測方法的核准制定了嚴格的標準，以確保只有最有效、最安全的診斷方法才能進入市場。雖然這些法規對於維護血流感染（BSI）檢測的品質和可靠性至關重要，但也為中小企業和Start-Ups公司設置了市場准入壁壘。此外，人們對抗生素抗藥性的日益關注也促使人們開發出不僅能夠識別病原體，還能提供抗生素敏感性資訊的BSI檢測方法，從而製定更有效的治療方案。

推動血液傳染病檢查市場成長的關鍵因素有哪些？

血液傳染病檢查市場的成長受多種因素驅動，包括院內感染（HAI）發病率的上升和抗藥性病原體的日益流行，這些因素增加了對快速準確診斷的需求。敗血症的全球負擔，尤其是在老化社會和免疫力缺乏患者群體中，也推動了對先進血流感染（BSI）檢測解決方案的需求。此外，個人化醫療的興起以及對病原體特異性精準治療方法的需求，正在推動BSI檢測中尖端分子診斷技術的應用。自動化和高通量檢測平台等技術的進步，提高了診斷速度，這對於有效管理BSI至關重要。此外，新興市場醫療基礎設施的不斷改善以及醫護人員和公眾對敗血症認知的提高，也促進了市場成長。隨著全球醫療系統持續重視感染控制和抗菌藥物管理，對高效可靠的血流感染檢測的需求預計將會增加，從而推動這一重要細分市場的進一步創新和擴張。

部分：

依技術分類（常規測試、非常規測試）

受訪公司範例

  • Abbott Laboratories
  • Becton, Dickinson & Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific, Inc.

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具，改變您分析市場和競爭情報的方式。

Global Industry Analysts 並沒有查詢通用的 LLM 或產業專用的SLM，而是建立了一個由世界各地領域專家精心策劃的內容庫，包括影片文字稿、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

我們最新發布的報告納入了關稅對區域市場的影響，正如全球產業分析師預測的那樣，關稅將改變企業的競爭地位，而企業的競爭地位將取決於其總部所在地、製造地以及進出口（成品和OEM產品）。這種複雜多變的市場現實將透過微觀和宏觀市場動態影響競爭對手，包括銷貨成本增加、盈利下降以及供應鏈重組。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 亞太其他地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP10753

Global Bloodstream Infection Testing Market to Reach US$17.1 Billion by 2030

The global market for Bloodstream Infection Testing estimated at US$11.5 Billion in the year 2024, is expected to reach US$17.1 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Conventional Testing, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$12.7 Billion by the end of the analysis period. Growth in the Non-Conventional Testing segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 10.4% CAGR

The Bloodstream Infection Testing market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2030 trailing a CAGR of 10.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Bloodstream Infection Testing Market - Key Trends and Drivers Summarized

Why Is Bloodstream Infection Testing a Cornerstone in Medical Diagnostics?

Bloodstream infection (BSI) testing plays a pivotal role in medical diagnostics, as it is crucial for the early detection and treatment of sepsis, a life-threatening condition caused by an overwhelming immune response to infection. BSIs can result from a variety of pathogens, including bacteria, fungi, and viruses, and their rapid identification is essential to prevent the progression to severe sepsis or septic shock, both of which are associated with high mortality rates. Timely BSI testing allows healthcare providers to administer appropriate antimicrobial therapies, thereby reducing the risk of complications and improving patient outcomes. As a cornerstone of infection control in hospitals, BSI testing is also vital in preventing the spread of infections, particularly in critical care units where patients are most vulnerable.

How Are Technological Innovations Transforming Bloodstream Infection Testing?

The landscape of bloodstream infection testing is being transformed by rapid advancements in technology, which are enhancing the speed, accuracy, and comprehensiveness of diagnostics. Traditional blood culture methods, which can take days to deliver results, are being supplemented or replaced by advanced molecular diagnostic techniques such as polymerase chain reaction (PCR), mass spectrometry, and next-generation sequencing (NGS). These technologies enable the rapid identification of pathogens, often within hours, allowing for earlier and more targeted treatment interventions. Additionally, the advent of point-of-care (POC) testing devices is bringing BSI diagnostics closer to the patient, facilitating quicker decision-making in emergency and remote healthcare settings. The integration of artificial intelligence (AI) and machine learning algorithms into diagnostic platforms is also enhancing the interpretation of complex data, leading to more accurate diagnoses and better patient management.

What Challenges and Regulatory Pressures Are Shaping the Bloodstream Infection Testing Market?

The bloodstream infection testing market is shaped by a complex interplay of challenges and regulatory pressures. One of the primary challenges is the need for highly sensitive and specific tests that can accurately identify a wide range of pathogens, including those that are difficult to culture or detect. This demand has led to significant investment in research and development, driving innovation in diagnostic technologies. At the same time, regulatory bodies such as the FDA and the European Medicines Agency impose stringent standards for the approval of new testing methods, ensuring that only the most effective and safe diagnostics are brought to market. These regulations are critical for maintaining the quality and reliability of BSI testing but also pose barriers to market entry for smaller companies and startups. Additionally, the growing concern over antibiotic resistance is influencing the development of BSI tests that can provide not only pathogen identification but also insights into antibiotic susceptibility, thereby guiding more effective treatment decisions.

What Are the Key Drivers Behind the Growth of the Bloodstream Infection Testing Market?

The growth in the bloodstream infection testing market is driven by several factors, including the rising incidence of hospital-acquired infections (HAIs) and the increasing prevalence of drug-resistant pathogens, which heighten the need for rapid and accurate diagnostics. The global burden of sepsis, particularly in aging populations and immunocompromised patients, is also fueling demand for advanced BSI testing solutions. Furthermore, the shift towards personalized medicine and the need for precise, pathogen-specific treatment regimens are driving the adoption of cutting-edge molecular diagnostics in BSI testing. Technological advancements, such as the development of automated and high-throughput testing platforms, are reducing the time to diagnosis, which is critical in managing BSIs effectively. Additionally, the expansion of healthcare infrastructure in emerging markets and the increasing awareness of sepsis among healthcare providers and the general public are contributing to market growth. As healthcare systems worldwide continue to prioritize infection control and antimicrobial stewardship, the demand for efficient and reliable bloodstream infection testing is expected to rise, driving further innovation and expansion in this critical market segment.

SCOPE OF STUDY:

The report analyzes the Bloodstream Infection Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Conventional Testing, Non-Conventional Testing)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Becton, Dickinson & Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Bloodstream Infection Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Incidence of Sepsis Propels Demand for Bloodstream Infection Testing
    • Rising Healthcare-Associated Infections Expand the Addressable Market Opportunity
    • Technological Innovations in Rapid Diagnostics Drive Market Growth
    • Adoption of Point-of-Care Testing Strengthens the Business Case for Faster Diagnostics
    • Increasing Antimicrobial Resistance Throws the Spotlight on Early Detection
    • Rising Awareness of Bloodstream Infections Spurs Market Expansion
    • Advancements in Molecular Testing Techniques Sustain Market Growth
    • Shift Towards Personalized Medicine Expands Market Potential
    • Here's the Story: How the Need for Rapid, Accurate Results Generates Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bloodstream Infection Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bloodstream Infection Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Bloodstream Infection Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Conventional Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Conventional Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Conventional Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Conventional Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Conventional Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-Conventional Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: USA 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: Canada 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • JAPAN
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: Japan 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • CHINA
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: China 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • EUROPE
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Bloodstream Infection Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Europe 15-Year Perspective for Bloodstream Infection Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • FRANCE
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: France 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • GERMANY
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Germany 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Italy 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: UK 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Spain 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Russia 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Bloodstream Infection Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 15-Year Perspective for Bloodstream Infection Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Australia 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • INDIA
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: India 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: South Korea 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Bloodstream Infection Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Latin America 15-Year Perspective for Bloodstream Infection Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Latin America 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Argentina 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Brazil 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Mexico 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Bloodstream Infection Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Middle East 15-Year Perspective for Bloodstream Infection Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Middle East 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Iran 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Israel 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UAE 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030
  • AFRICA
    • Bloodstream Infection Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Bloodstream Infection Testing by Technology - Conventional Testing and Non-Conventional Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Africa 15-Year Perspective for Bloodstream Infection Testing by Technology - Percentage Breakdown of Value Sales for Conventional Testing and Non-Conventional Testing for the Years 2015, 2025 & 2030

IV. COMPETITION